Ryman rights trading ends on a sour note

Ryman rights trading ends on a sour note
Salt Funds' Matt Goodson said time will tell whether Ryman shares are cheap. (Image: Salt Funds)
Jenny Ruth
Ryman Healthcare’s $902 million rights issue is drawing to a dismal close, with the price of the rights falling as low as 7.5 cents on Tuesday, the last day of trading.Two weeks ago, in the institutional book-build auction process, institutional investors were prepared to pay an effective $1 for the rights.You could say that was a little disappointing because the theoretical value of the rights price was $1.03 – institutions paid $6 for the shares issued at $5, so the additional price paid reflected the value they put on the rights....

More Finance

Cautious lending keeps lid on default rates – Reserve Bank
Finance

Cautious lending keeps lid on default rates – Reserve Bank

Non-performing mortgages have overtaken Covid levels.

Jem Traylen 01 May 2024
'Confirmation of payee' anti-scam measure inches closer
Finance

'Confirmation of payee' anti-scam measure inches closer

Banks are getting closer to implementing anti-scam “confirmation of payee” measures.

Dileepa Fonseka 30 Apr 2024
UBS NZ returns to profit
Finance

UBS NZ returns to profit

Operating income was up 51.8%, rising from $31.9m in 2022 to $48.5m in 2023.

Murray Jones 30 Apr 2024
Matt Whineray to chair new FirstCape Group fund manager and adviser
Finance

Matt Whineray to chair new FirstCape Group fund manager and adviser

The new entity aims to scale up advice and fund management services in NZ.

Staff reporters 23 Apr 2024